- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05571189
Rehabilitación domiciliaria después de una embolia pulmonar aguda
The purpose of this study is to evaluate whether a home rehabilitation program after hospitalization for acute pulmonary embolism (PE) improves clinical outcomes at 3 months compared to usual care. Daily physical activity tasks that incorporate heart rate monitoring will be sent through email or text. This information could help improve the management of acute PE.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New York
-
Rochester, New York, Estados Unidos, 14642
- University of Rochester Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- English speaking (>18 years old). Daily messages will be sent in English.
- Acute PE with right ventricular enlargement or dysfunction defined by echocardiogram report, CT Angiogram report, or elevated cardiac biomarker (NT-pro BNP or troponin).
- Baseline testing started within 7 days of hospital discharge.
Exclusion Criteria:
- Pregnancy.
- Cardiac Effort >2.5 beats/m during 6MWT. This is for safety.
- Cardiac Effort <1.2 beats/m during 6MWT. They are unlikely to benefit.
- Resting tachycardia >120 beats/m during screening or at hospital discharge.
- Suspicion for Chronic Thromboembolic Pulmonary Hypertension.
- Systolic blood pressure >180 mmHg during screening or at hospital discharge.
- Inability to walk.
- Estimated prognosis <12 months at the time of discharge due to underlying co-morbidities.
- Advanced neurologic disease.
- Lack of access to email or text messaging.
- Inability to follow daily instructions.
- Participation in a structured exercise routine at least three days per week in the prior four weeks.
- Principal Investigator discretion
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Participants who receive daily activity message
The intervention group will receive instructions for a daily activity sent through SMS text message or email. |
Participants will receive a text each day with instructions about the daily activity they should complete for that day. |
|
Comparador de placebos: Participants who receive control message
The control group will receive daily messages to help with blinding sent through text message or email. The messages will not include activity tasks and will include phrases such as "I hope you have a good day". |
Participants will receive a text each day with no instructions about daily activity. It will have messages like "have a nice day." |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
mean change in vector magnitude count as measured by actigraphy
Periodo de tiempo: 10 weeks
|
The Actigraph triaxial accelerometer will be used to monitor continuous activity at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the vector magnitude count. |
10 weeks
|
|
mean change in mean amplitude deviation as measured by actigraphy
Periodo de tiempo: 10 weeks
|
The Actigraph triaxial accelerometer will be used to monitor continuous activity at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the mean amplitude deviation. |
10 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
cambio medio en 6 minutos de distancia a pie
Periodo de tiempo: 12 semanas
|
12 semanas
|
|
|
cambio medio en la frecuencia cardiaca durante una caminata de 6 minutos
Periodo de tiempo: 12 semanas
|
12 semanas
|
|
|
proporción de sujetos que desarrollan hipertensión pulmonar tromboembólica crónica
Periodo de tiempo: 12 semanas
|
12 semanas
|
|
|
proportion of participants with post-PE syndrome
Periodo de tiempo: 12 weeks
|
Participants will be evaluated by a physician to determine if they have post PE-syndrome |
12 weeks
|
|
mean change in steps as measured by Actigraph
Periodo de tiempo: 12 weeks
|
The Actigraph triaxial accelerometer will be used to monitor the number of steps taken at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the step count. |
12 weeks
|
|
mean change in activity as measured by Actigraph
Periodo de tiempo: 12 weeks
|
The Actigraph triaxial accelerometer will be used to monitor the amount of activity taken at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the amount of activity. |
12 weeks
|
|
mean change in quality of life as measured by PROMIS
Periodo de tiempo: 12 weeks
|
The PROMIS questionnaire ranges from 0-99 with higher scores indicating worse outcome. |
12 weeks
|
|
mean change in quality of life as measured by Emphasis 10
Periodo de tiempo: 12 weeks
|
The Emphasis 10 questionnaire ranges from 0-50 with higher scores indicating worse quality of life. |
12 weeks
|
|
mean change in quality of life as measured by Pulmonary Embolism quality of life questionnaire
Periodo de tiempo: 12 weeks
|
The pulmonary embolism quality of life questionnaire ranges from 1 to 27 with higher scores indicating worse outcomes. |
12 weeks
|
|
mean change in oxygen use during a 6 minute walk
Periodo de tiempo: 12 weeks
|
Oxygen use will be measured by a measured by portable K5 metabolic analyzer. |
12 weeks
|
|
mean change in carbon dioxide production during a 6 minute walk
Periodo de tiempo: 12 weeks
|
Carbon Dioxide use will be measured by a measured by portable K5 metabolic analyzer. |
12 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Daniel Lachant, DO, University of Rochester
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- STUDY00007680
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .